Form 4: Lucid Diagnostics CFO Dennis McGrath Acquires 300,000 Shares of Common Stock

Lucid Diagnostics' Chief Financial Officer, Dennis McGrath, reports acquiring 300,000 shares of common stock through a restricted stock grant.

Summary

• Dennis McGrath, the Chief Financial Officer of Lucid Diagnostics Inc., filed a Form 4 disclosing changes in his beneficial ownership of the company's stock.
• On February 20, 2025, McGrath acquired 300,000 shares of Lucid Diagnostics common stock.
• These shares were granted as restricted stock under the Issuer's 2018 Equity Plan and will vest on May 20, 2028, contingent upon continued service.
• The acquisition was priced at $0.
• Following the transaction, McGrath beneficially owns 1,343,569 shares of Lucid Diagnostics common stock.
• This total includes 19,169 shares distributed by PAVmed on February 15, 2024, representing McGrath's pro-rata share of Lucid common stock distributed to PAVmed shareholders.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by the CFO suggests confidence in the company, but it's a standard transaction related to compensation.

Positives

• The acquisition of shares by a key executive like the CFO can be seen as a positive sign, indicating confidence in the company's future prospects.

Risks

• The restricted stock is subject to forfeiture if the service period is not completed, which could be a risk if McGrath were to leave the company before the vesting date.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the restricted stock on May 20, 2028, implies a long-term commitment from the CFO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the stock ownership of company insiders. This filing indicates the CFO's continued investment in the company.

Stakeholder Impact

• The increased ownership by a key executive could positively influence investor sentiment.

Key Dates

Keywords

Lucid Diagnostics, Dennis McGrath, CFO, Form 4, Beneficial Ownership, Restricted Stock, Equity Plan, Share Acquisition